The findings in this open-label nonrandomized controlled trial suggest efficacy and safety of psilocybin with psychotherapy in BDII depression and supports further study of psychedelics in this population.

Tim Ferriss talks with Dr Willoughby Britton about her ground-breaking (and often unpopular) research highlighting potential dangers and worrying frequency of adverse effects associated with meditation practices (and similarly psychedelics).

We conclude that VHD is a potential risk with chronic psychedelic microdosing, but further studies are necessary to better define this risk.

The Virtual Trip is filling your table full of psychedelic sessions for your holiday week. Grab your laptop or phone, a warm drink, and your stretchy pants, and get ready to enjoy our largest video release yet

Goldstein helps train other facilitators and guides psilocybin sessions with clients in Bend, Oregon ... We spoke with Goldstein about his role as a licensed facilitator, and how it differs from his work in the underground.

We show how conceiving of post-trial provision as an integral site of the research process, and an appropriate destination for research funding, will serve to develop the infrastructure necessary for the post-legalisation psychedelic medicine ecosystem.

PAP is a highly unique and transdisciplinary intervention, and future research designs should consider transdisciplinary research methodologies to identify best practices and inform federal guidelines for PAP administration.

We infer that the presence of a personality disorder may represent an elevated risk for psychedelic use, and hypothesize that the importance of psychological support and good therapeutic alliance may be increased in this population.

Trait mindfulness, specifically description and non-judging of inner experience, was increased, and neuroticism was decreased after 4  weeks of MD compared to baseline. The remaining personality traits remained unchanged. Using conventional medication and/or having comorbid diagnoses did not change the MD-induced effects on mindfulness and personality traits after 4  weeks. Conclusion: MD induced changes in otherwise stable traits. Future placebo-controlled studies are warranted to confirm whether these changes occur in a controlled setting.

Ketamine has the potential to change our approach to the clinical management of depression if knowledge, attitudinal, and regulatory barriers can be overcome, and if risks related to comorbidities and concurrent medications are addressed by close supervision.

Insights and subsequent life and lifestyle changes appear to have a central role in the transformative effects reported by individuals consuming ayahuasca, with these occurring across contexts of use and demographic groups.